Advancing RNA Therapeutics for Huntington’s Disease

推进亨廷顿病的 RNA 疗法

基本信息

批准号：
10087978
负责人：
NEIL ARONIN
金额：
$ 150.58万
依托单位：
UNIV OF MASSACHUSETTS MED SCH WORCESTER
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-02-01 至 2025-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10087978
关键词：
Affect Age Amyotrophic Lateral Sclerosis Animal Disease Models Biological Assay Blood Chemical Analysis Bolus Infusion Brain Brain Diseases Brain region CAG repeat Care given by nurses Cerebral Dominance Cerebral Ventricles Cerebrospinal Fluid Chemicals Chemistry Child Complete Blood Count Coupling Crowding DARPP Data Dementia Discipline of Nursing Disease Dose Drug Stability Dyskinetic syndrome Economic Burden Economics Evaluation Exhibits Family Female Filtration Formulation Frontotemporal Dementia Genes Genetic Glial Fibrillary Acidic Protein Goals Gross National Product Head Health Benefit High Pressure Liquid Chromatography Human Huntington Disease Huntington gene Huntington protein Hydrophobicity Impaired cognition Individual Inherited Injections Lateral Magnetic Resonance Imaging Measures Mental Depression Messenger RNA Modification Movement Mus Mutation Neostriatum Neurodegenerative Disorders Neurons Onset of illness Outcome Outcome Measure Parents Patients Process Production Property Proteins Public Health RNA Interference Route Safety Secure Severity of illness Small Interfering RNA Societies Spinal Stress Structure Testing Therapeutic Time Toxic effect Transgenic Organisms Western Blotting Work base cytokine drug testing effective therapy flexibility in vivo lateral ventricle lead candidate male motor impairment mutant nervous system disorder neuropathology nonhuman primate phosphoramidite polyglutamine pressure process optimization programs public health relevance research clinical testing response therapeutic RNA uptake

项目摘要

ABSTRACT The cause of Huntington’s disease is an increase in the trinucleotide CAG repeat from under 36 repeats to 36 or greater repeats. The mode for the number of repeats is 42, and most patients have between 40 and 45. The disease generally starts between ages 30 and 40, with onset and progression of impaired cognition, depression, and aberrant movement. The genetics is autosomal dominant. Lowering mutant huntingtin in HD animal models delays onset of disease or mitigates the severity of disease. We use advanced, modified, di- branched siRNA to lower mutant huntingtin, by invoking RNA interference in brain. Our advanced siRNA achieves therapeutic advantages: spread throughout the brain in non- human primate and long-term huntingtin lowering after a single administration into the cerebrospinal fluid. The siRNA will be optimized in structure for safety and preliminary results will be secured. The goal of this CREATE proposal is to set the stage for promising therapeutics for treatment of Huntington’s disease. Similar treatments could be applicable to other autosomal dominant neurological disorders.

抽象的亨廷顿病的病因是三核苷酸 CAG 重复序列从下方增加 36 次重复至 36 次或更多重复重复次数的模式为 42，最多。患者年龄在40岁至45岁之间。该病一般在30岁至40岁之间开始，随着认知障碍、抑郁和运动异常的发生和进展。遗传学是常染色体显性遗传，在 HD 动物模型中降低突变亨廷顿蛋白延迟。我们使用先进的、改良的、di- 来控制疾病的发生或减轻疾病的严重程度。分支 siRNA 通过在大脑中调用 RNA 干扰来降低突变亨廷顿蛋白。先进的 siRNA 实现了治疗优势：以非人类灵长类动物和长期亨廷顿蛋白在单次给药后降低为了安全性和初步性，将对 siRNA 进行结构优化。该 CREATE 提案的目标是为有希望的事情奠定基础。类似的治疗方法也适用于亨廷顿病。其他常染色体显性神经系统疾病。